Journal
PROTEIN AND PEPTIDE LETTERS
Volume 16, Issue 12, Pages 1548-1556Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/092986609789839232
Keywords
hGLP-1; protein aggregation; biopharmaceuticals; diabetes; amyloid fibrils; Alzheimer's disease
Categories
Funding
- Zyentia Ltd.
- Wellcome and Leverhulme Trusts
Ask authors/readers for more resources
The potential of human glucagon-like peptide-1 (hGLP-1) as a therapeutic agent is limited by its high aggregation propensity. We show that hGLP-1 forms amyloid-like structures that are preceded by cytotoxic aggregates, suggesting that aggregation of biopharmaceuticals could present a cytotoxic risk to patients besides the reported increased risk in immunogenicity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
